Physician profile
Alan N Brown
NPI 1760590624
$947,395.80
in general payments reported to CMS, 2019-2025
22 companies · $239K in 2025
The $239K reported for 2025 was more than what 99% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49K · 2020: $67K · 2021: $83K · 2022: $132K · 2023: $184K · 2024: $192K · 2025: $239K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $453K · Travel and Lodging: $122K · Consulting Fee: $23K · Food and Beverage: $17K · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $452,854.00 |
| Travel and Lodging | $121,786.32 |
| Consulting Fee | $23,410.00 |
| Food and Beverage | $17,343.72 |
| Education | $101.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $785,290.43 | 2019-2025 | Rinvoq, Skyrizi |
| Mallinckrodt Hospital Products INC. | $59,352.02 | 2020-2025 | Acthar |
| Ucb, INC. | $46,932.93 | 2020-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $45,157.71 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $5,251.12 | 2022-2025 | Strensiq |
| Janssen Biotech, INC. | $2,826.81 | 2021-2025 | Tremfya, Simponi Aria |
| Genentech USA, INC. | $741.23 | 2019-2023 | Actemra |
| Amgen INC. | $452.11 | 2023-2025 | Krystexxa, Enbrel, Tavneos |
| Pfizer INC. | $290.30 | 2020-2025 | |
| Astrazeneca Pharmaceuticals Lp | $271.06 | 2021-2023 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $250.64 | 2021-2024 | |
| Glaxosmithkline, LLC. | $130.10 | 2019-2025 | Benlysta |
| Radius Health, INC. | $108.10 | 2025 | Tymlos |
| Sanofi-Aventis U.S. LLC | $88.60 | 2024 | |
| Lilly USA, LLC | $78.46 | 2020-2023 | Taltz |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.59 | 2025 | |
| Aurinia Pharma U.S., INC. | $31.95 | 2021 | |
| Organon LLC | $29.94 | 2024 | |
| Ani Pharmaceuticals, INC. | $22.75 | 2024 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $18.42 | 2023 | Krystexxa |
| Teva Pharmaceuticals USA, INC. | $17.58 | 2025 | Austedo Xr |
| Viiv Healthcare Company | $13.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.